Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Doses of KD025 in Healthy Volunteers
NCT05918588Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of belumosudil in chronic graft-versus-host disease (cGVHD) (4 cohorts), sponsored by Sanofi. Primary endpoint: Number of participants with adverse events and serious adverse events up to 37 days. Started Nov 2013; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05918588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918588.